Results overview: Found 1 records in 0.01 seconds.
Articles, 1 records found
Articles 1 records found  
7 p, 199.8 KB CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer / Chiorean, E. G. (University of Washington. Department of Medicine) ; Von Hoff, D. D. (Translational Genomics Research Institute) ; Reni, M. (Ospedale San Raffaele. Servizio di Oncologia Medica) ; Arena, F. P. (NYU Langone Arena Oncology. Department of Oncology) ; Infante, J. R. (Sarah Cannon Research Institute) ; Bathini, V. G. (University of Massachusetts Medical School. Cancer Center of Excellence) ; Wood, T. E. (University of Alabama at Birmingham. Comprehensive Cancer Center) ; Mainwaring, P. N. (Centre for Haematology & Oncology (Brisbane, Austràlia)) ; Muldoon, R. T. (Genesis Cancer Center. Department of Oncology) ; Clingan, P. R. (Southern Medical Day Care Centre) ; Kunzmann, V. (Universitätsklinikum Würzburg. Medizinischen Klinik und Poliklinik II) ; Ramanathan, R. K. (Translational Genomics Research Institute) ; Taberneroo, J (Hospital Universitari Vall d'Hebron) ; Goldstein, D. (Prince of Wales Hospital. Department of Oncology) ; McGovern, D. (Celgene Corporation) ; Lu, B. (Celgene Corporation) ; Ko, A. (Celgene Corporation) ; Universitat Autònoma de Barcelona
Any CA19-9 decline at week 8 and radiologic response by week 8 each predicted longer OS in both treatment arms. In the nab- P + Gem arm, the higher proportion of patients with week 8 CA19-9 decrease [82% (206/252); median OS 13. [...]
2016 - 10.1093/annonc/mdw006
Annals of oncology, Vol. 27, issue 4 (April 2016) , p. 654-660  

See also: similar author names
1 Arena, F.
1 Arena, F. P.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.